Federal contract award
75A50122C00072
ENALARE THERAPEUTICS: AN AGNOSTIC RESPIRATORY STIMULANT FOR USE AS A MEDICAL COUNTERMEASURE TO TREAT RESPIRATORY DEPRESSION
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | BARDA - ASPR / DAAPPO / BARDA DCMA |
| NAICS | 541714 — Research and Development in Biotechnology (except Nanobiotechnology) |
| PSC | AN13 — HEALTH R&D SERVICES; HEALTH CARE SERVICES; EXPERIMENTAL DEVELOPMENT |
| Parent award / vehicle | Not reported |
| Set-aside | NO SET ASIDE USED. |
| Pricing type | COST PLUS FIXED FEE |
| Obligations | $12.2M |
| Current contract value | $12.2M |
| Potential contract value / ceiling | $56.6M |
| Start date | Sep 22, 2022 |
| Current end date | Dec 31, 2026 |
| Potential end date | Sep 30, 2028 |
| Latest award activity | May 18, 2026 |
| Source loaded | Sep 26, 2026 |
Funding and modification history
Showing the latest 7 of 7 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| May 18, 2026 | P00006 | $810.1K | THE PURPOSE OF THIS MODIFICATION IS TO EXTEND CLIN0001/BASE THROUGH DECEMBER 31, 2026, PROVIDE SUPPLEMENTAL FUNDING TO SUPPORT THE DEVELOPMENT OF INTRAMUSCULAR (IM) ENA-001 FOR SUBMISSION TO THE US FOOD AND DRUG ADMINISTRATION, UPDATE SECTION I.1 FED |
| Dec 15, 2025 | P00005 | $0 | THE PURPOSE OF THIS MODIFICATION IS TO EXTEND CLIN0001/BASE THROUGH SEPTEMBER 30, 2026, AT NO ADDITIONAL COST TO THE GOVERNMENT, UPDATE SECTIONS B.2 BASE PERIOD, F.2 DELIVERABLES, G.2 CONTRACTING OFFICER?S REPRESENTATIVE (COR), AND G.3 KEY PERSONNEL. |
| Sep 5, 2024 | P00004 | $5.0M | THE PURPOSE OF THIS MODIFICATION IS TO PROVIDE SUPPLEMENTAL FUNDING TO CLIN0001 TO SUPPORT THE DEVELOPMENT OF THE AGNOSTIC RESPIRATORY STIMULANT ENA-001, UPDATE SECTIONS F.2 DELIVERABLES, G.1. CONTRACTING OFFICER, G.4 FINANCIAL REPORT, AND ATTACHMENT |
| Mar 25, 2024 | P00003 | $0 | NO COST EXTENSION FOR CLIN0001 THROUGH JANUARY 31, 2026 |
| Sep 30, 2023 | P00002 | $0 | CORRECT ERROR FROM P00001 |
| Sep 20, 2023 | P00001 | $469.3K | PROVIDE SUPPLEMENTAL FUNDING FOR ENA-001 |
| Sep 22, 2022 | 0 | $6.0M | ENALARE THERAPEUTICS: AN AGNOSTIC RESPIRATORY STIMULANT FOR USE AS A MEDICAL COUNTERMEASURE TO TREAT RESPIRATORY DEPRESSION |
Estimated positioning window
Sep 30, 2027 – Mar 30, 2028
70/100
Why this recompete signal
Contract timing and recorded acquisition signals at the time of calculation.
Stored score: 70/100. Available recorded signals: 65 points.
- Contract end 2028-09-30 (706 days from calculation)
- +25 points
- 121 historical awards in this buyer and category group
- +15 points
- 7 recorded award transactions
- +10 points
- Latest award action: 2026-05-18
- +5 points
- Parent award identifier recorded
- +0 points
- Solicitation identifier recorded
- +10 points
- Linked official forecast
- +0 points
- Calculated on
- 2026-10-25 10:18:04.631876+00:00
The historical group combines buyer, NAICS, and PSC. Multiple awards in this group do not by themselves establish repeated competitions.
Rule-based research score; it does not measure your chance of winning.
This older calculation does not retain a complete reproducible breakdown. Missing or changed inputs are not assigned invented points: Original award-value bonus input.
Recompete score calculated Oct 25, 2026.
Research next steps
- Check the linked forecast or SAM for a confirmed solicitation and current timing.
- Verify whether remaining options may extend performance beyond the current end date.
- Check the stated set-aside against the solicitation and current certifications.
- Review the award scope and buyer evidence before making a bid/no-bid decision.